Literature DB >> 33451143

Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection.

Mohammed El-Mowafy1, Abdelaziz Elgaml1,2, Mohamed El-Mesery3, Salma Sultan4, Tamer A E Ahmed4,5, Ahmed I Gomaa4,6, Mahmoud Aly4,7, Walid Mottawea1,4.   

Abstract

The gut-liver-axis is a bidirectional coordination between the gut, including microbial residents, the gut microbiota, from one side and the liver on the other side. Any disturbance in this crosstalk may lead to a disease status that impacts the functionality of both the gut and the liver. A major cause of liver disorders is hepatitis C virus (HCV) infection that has been illustrated to be associated with gut microbiota dysbiosis at different stages of the disease progression. This dysbiosis may start a cycle of inflammation and metabolic disturbance that impacts the gut and liver health and contributes to the disease progression. This review discusses the latest literature addressing this interplay between the gut microbiota and the liver in HCV infection from both directions. Additionally, we highlight the contribution of gut microbiota to the metabolism of antivirals used in HCV treatment regimens and the impact of these medications on the microbiota composition. This review shed light on the potential of the gut microbiota manipulation as an alternative therapeutic approach to control the liver complications post HCV infection.

Entities:  

Keywords:  HCV; antiviral drugs; dysbiosis; gut liver axis; gut microbiota

Year:  2021        PMID: 33451143      PMCID: PMC7828638          DOI: 10.3390/biology10010055

Source DB:  PubMed          Journal:  Biology (Basel)        ISSN: 2079-7737


  208 in total

Review 1.  The interaction of hepatic lipid and glucose metabolism in liver diseases.

Authors:  Lars P Bechmann; Rebekka A Hannivoort; Guido Gerken; Gökhan S Hotamisligil; Michael Trauner; Ali Canbay
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

2.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

Review 3.  Clinical significance of hepatitis C virus genotypes.

Authors:  N N Zein
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

4.  The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis.

Authors:  Celine Cosseau; Deirdre A Devine; Edie Dullaghan; Jennifer L Gardy; Avinash Chikatamarla; Shaan Gellatly; Lorraine L Yu; Jelena Pistolic; Reza Falsafi; John Tagg; Robert E W Hancock
Journal:  Infect Immun       Date:  2008-07-14       Impact factor: 3.441

5.  Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.

Authors:  Ursula Andréo; Patrick Maillard; Olga Kalinina; Marine Walic; Eliane Meurs; Michèle Martinot; Patrick Marcellin; Agata Budkowska
Journal:  Cell Microbiol       Date:  2007-05-21       Impact factor: 3.715

Review 6.  Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination.

Authors:  Viktorija Basyte-Bacevice; Juozas Kupcinskas
Journal:  Dig Dis       Date:  2020-01-06       Impact factor: 2.404

Review 7.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

8.  Hepatitis C virus genotypes 1 and 2 respond to interferon-alpha with different virologic kinetics.

Authors:  M Kohara; T Tanaka; K Tsukiyama-Kohara; S Tanaka; M Mizokami; J Y Lau; N Hattori
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

9.  The role of gut microbiota in liver disease development and treatment.

Authors:  Lijun Wang; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2019-02-20

10.  Bilberry Anthocyanins Ameliorate NAFLD by Improving Dyslipidemia and Gut Microbiome Dysbiosis.

Authors:  Hironobu Nakano; Shusong Wu; Kozue Sakao; Taichi Hara; Jianhua He; Santos Garcia; Kalidas Shetty; De-Xing Hou
Journal:  Nutrients       Date:  2020-10-23       Impact factor: 5.717

View more
  7 in total

1.  Sesamol protects against liver fibrosis induced in rats by modulating lysophosphatidic acid receptor expression and TGF-β/Smad3 signaling pathway.

Authors:  Nesma A Abd Elrazik; Mohamed El-Mesery; Mamdouh M El-Shishtawy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-06-01       Impact factor: 3.195

2.  Potential impact of gut Lactobacillus acidophilus and Bifidobacterium bifidum on hepatic histopathological changes in non-cirrhotic hepatitis C virus patients with different viral load.

Authors:  Zeinab Ashour; Rasha Shahin; Zeinab Ali-Eldin; Mohamed El-Shayeb; Tarek El-Tayeb; Salwa Bakr
Journal:  Gut Pathog       Date:  2022-06-15       Impact factor: 5.324

3.  Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report.

Authors:  Yumiko Nagao; Masahide Tsuji
Journal:  Int J Dent       Date:  2021-11-11

Review 4.  Gut Microbiota Extracellular Vesicles as Signaling Molecules Mediating Host-Microbiota Communications.

Authors:  Salma Sultan; Walid Mottawea; JuDong Yeo; Riadh Hammami
Journal:  Int J Mol Sci       Date:  2021-12-06       Impact factor: 5.923

Review 5.  Hepatocellular Carcinoma: Understanding the Inflammatory Implications of the Microbiome.

Authors:  Ahamed A Khalyfa; Shil Punatar; Alex Yarbrough
Journal:  Int J Mol Sci       Date:  2022-07-25       Impact factor: 6.208

Review 6.  The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.

Authors:  Nadia Marascio; Carmen De Caro; Angela Quirino; Maria Mazzitelli; Emilio Russo; Carlo Torti; Giovanni Matera
Journal:  J Clin Med       Date:  2022-10-08       Impact factor: 4.964

Review 7.  Hydrogen Sulfide Produced by Gut Bacteria May Induce Parkinson's Disease.

Authors:  Kari Erik Murros
Journal:  Cells       Date:  2022-03-12       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.